Analysts Set TG Therapeutics, Inc. (NASDAQ:TGTX) Target Price at $40.67

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $40.67.

Several equities analysts have commented on TGTX shares. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Wednesday, January 15th. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. TD Cowen started coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price for the company. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research note on Monday, November 25th. Finally, StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st.

Insider Activity at TG Therapeutics

In other news, CFO Sean A. Power sold 11,337 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total value of $343,397.73. Following the completion of the transaction, the chief financial officer now owns 670,632 shares of the company’s stock, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 10.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. NBC Securities Inc. increased its stake in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares during the period. Blue Trust Inc. increased its position in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares during the period. Smartleaf Asset Management LLC raised its holdings in TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 1,737 shares during the period. Finally, ORG Wealth Partners LLC bought a new stake in shares of TG Therapeutics in the 3rd quarter valued at $53,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Stock Performance

TGTX opened at $32.25 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics has a 52-week low of $12.84 and a 52-week high of $36.84. The firm has a market cap of $5.02 billion, a P/E ratio of -322.47 and a beta of 2.26. The business’s fifty day moving average is $31.38 and its 200-day moving average is $27.11.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.